- Record: found
- Abstract: found
- Article: not found
PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
Luis G Paz-Ares
1 ,
Filippo de Marinis ,
Mircea Dediu ,
Michael Thomas ,
Jean-Louis Pujol ,
Paolo Bidoli ,
Olivier Molinier ,
Tarini Prasad Sahoo ,
Eckart Laack ,
Martin Reck ,
Jesús Corral ,
Symantha Melemed ,
William John ,
Nadia Chouaki ,
Annamaria H Zimmermann ,
Carla Visseren-Grul ,
Cesare Gridelli
Aug 10 2013
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
In the phase III PARAMOUNT trial, pemetrexed continuation maintenance therapy reduced the risk of disease progression versus placebo (hazard ratio [HR], 0.62; 95% CI, 0.49 to 0.79; P < .001). Here we report final overall survival (OS) and updated safety data.